Genetic polymorphisms in human Cyp2a6 gene and interindividual differences in nicotine metabolism

被引：0
|
作者：
Nakajima, M [1 ]
Yoshida, R [1 ]
Nishimura, K [1 ]
Kwon, JT [1 ]
Yokoi, T [1 ]
机构：
[1] Kanazawa Univ, Fac Pharmaceut Sci, Div Drug Metab, Kanazawa, Ishikawa 920, Japan
来源：
CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM | 2003年
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
We determined the phenotyping of in vivo nicotine metabolism and the genotyping of the CYP2A6 gene in 92 Japanese and 209 Koreans. Among them, 3 Japanese and 4 Korean subjects who were absolutely deficient in cotinine formation were genotyped as CYP2A6*4 (whole deletion)/CYP2A6*4. The other poor metabolizers whose nicotine metabolism was impaired were genotyped as CYP2A6*4/CYP2A6*7 (I471T) or CYP2A6*4/CYP2A6*10 (I471T, R485L). The cotinine/nicotine ratio as an index of nicotine metabolism could be put in the order of subjects genotyped as CYP2A6*1A/CYP2A6*1A > CYP2A6*1A/ CYP2A6*9 (T-48G) > CYP2A6*9/CYP2A6*9. Thus, nicotine metabolism was impaired by CYP2A6*4, CYP2A6*7, and CYP2A6*10 alleles and was decreased by CYP2A6*9 allele.
引用
收藏
页码：257 / 260
页数：4
相关论文
共 50 条
  • [41] The significance of the homozygous CYP2A6 deletion on nicotine metabolism:: A new genotyping method of CYP2A6 using a single PCR-RFLP
    Kitagawa, K
    Kunugita, N
    Katoh, T
    Yang, MH
    Kawamoto, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) : 146 - 151
  • [42] Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted
    Yamanaka, H
    Nakajima, M
    Nishimura, K
    Yoshida, R
    Fukami, T
    Katoh, M
    Yokoi, T
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 22 (05) : 419 - 425
  • [43] CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers
    Chenoweth, Meghan J.
    O'Loughlin, Jennifer
    Sylvestre, Marie-Pierre
    Tyndale, Rachel F.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (04): : 232 - 235
  • [44] Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine
    Endo, Takuro
    Nakajima, Miki
    Fukami, Tatsuki
    Hara, Yoshiki
    Hasunuma, Tomoko
    Yokoi, Tsuyoshi
    Momose, Yasunori
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (09): : 761 - 772
  • [45] Coumarin inhibits CYP2A6 and nicotine (NIC) metabolism in vitro but not in vivo.
    Tyndale, RF
    Kaplan, HL
    Zhang, W
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 166 - 166
  • [46] Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations
    Claw, Katrina G.
    Beans, Julie A.
    Lee, Seung-Been
    Avey, Jaedon P.
    Stapleton, Patricia A.
    Scherer, Steven E.
    El-Boraie, Ahmed
    Tyndale, Rachel F.
    Nickerson, Deborah A.
    Dillard, Denise A.
    Thummel, Kenneth E.
    Robinson, Renee F.
    NICOTINE & TOBACCO RESEARCH, 2020, 22 (06) : 910 - 918
  • [47] Metabolism of (-)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes
    Miyazawa, M.
    Gyoubu, K.
    XENOBIOTICA, 2007, 37 (02) : 194 - 204
  • [48] Oral contraceptives induce CYP2A6 activity and accelerate nicotine metabolism.
    Benowitz, NL
    Swan, GL
    Lessov, CN
    Jacob, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P36 - P36
  • [49] CYP2A6 polymorphism, nicotine, and environmental nitrosamines
    Idle, JR
    LANCET, 1999, 353 (9169): : 2073 - 2073
  • [50] CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation
    Kubota, T
    Nakajima-Taniguchi, C
    Fukuda, T
    Funamoto, M
    Maeda, M
    Tange, E
    Ueki, R
    Kawashima, K
    Hara, H
    Fujio, Y
    Azuma, J
    PHARMACOGENOMICS JOURNAL, 2006, 6 (02): : 115 - 119
12345